Efficacy of liraglutide added to sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post‐hoc analysis of LIRA‐ADD2SGLT2i

por Blonde, Lawrence, Fainberg, Udi, Kaltoft, Margit S., Mosenzon, Ofri, Ramesh, Chethana, Rea, Rosangela
Publicado 2021

Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide

por Verma, Subodh, Fainberg, Udi, Husain, Mansoor, Rasmussen, Søren, Rydén, Lars, Ripa, Maria Sejersten, Buse, John B.
Publicado 2021

OR22-1 Liraglutide as Add-on to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double-Blind, Placebo-Controlled...

por Blonde, Lawrence, Belousova, Lidia, Fainberg, Udi, Garcia-Hernandez, Pedro, Jain, Sunil, Kaltoft, Margit, Mosenzon, Ofri, Nafach, Jalal, Palle, Mads, Réa, Rosangela
Publicado 2019

Liraglutide as add‐on to sodium‐glucose co‐transporter‐2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind,...

por Blonde, Lawrence, Belousova, Lidia, Fainberg, Udi, Garcia‐Hernandez, Pedro A., Jain, Sunil M., Kaltoft, Margit S., Mosenzon, Ofri, Nafach, Jalal, Palle, Mads Sundby, Rea, Rosangela
Publicado 2020